Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!
Jun 14, 2018
Idera's dermatomyositis drug missed primary endpoint in phase 2 Idera’s toll-like receptor (TLR) antagonist, IMO-8400, failed to meet its primary endpoint in a phase 2 trial carried on adults with dermatomyositis. Data has shown that the drug was meant to block TLR 7, 8 and 9 but failed to beat placebo in making a s...
Read More...
Roche’s HER2-Positive Breast Cancer Treatment Franchise
Aug 13, 2024
Transforming Multiple Myeloma Treatment: The Promise of Novel Drug Classes
Jul 24, 2024
-Agonist.png "Toll-like Receptors Agonist")
Newsletter/Whitepaper